Evidence map›Paper›PMID 38084956›Full record

ArticleJournal of virology2024

Hepatitis C virus modified sE2

Yuki Haga, Keith Meyer, Molly M H Sung, Erin K Reagan, Drew Weissman, Ranjit Ray

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Hepatitis C virus modifiedJournal of virology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuki HagaDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.ORCID 0000-0002-0070-2091
Keith MeyerDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.ORCID 0000-0002-1940-6006
Molly M H SungAcuitas Therapeutics, Vancouver, Canada.
Erin K ReaganDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ranjit RayDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.ORCID 0000-0001-8813-3446

Funding

Nucleoside modified mRNA based HIV vaccineR01AI124429 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2016 to 2019
$3.4M
SELECTION OF VACCINE ANTIGENS FOR PROTECTION FROM HEPATITIS C VIRUS INFECTIONR01DK122401 · NIDDK · SAINT LOUIS UNIVERSITY · PI RAY, RANJIT · 2020 to 2024
$1.7M
QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANSR01AI068769 · NIAID · SAINT LOUIS UNIVERSITY · PI RAY, RANJIT · 2006 to 2009
$1.3M
NIAID NIH HHS R01 AI068769NIAID NIH HHS R01 AI124429NIDDK NIH HHS R01 DK122401
6 · The paper itself

Abstract

The rational selection of hepatitis C virus (HCV) vaccine antigen will aid in the prevention of future chronic liver disease burden and associated healthcare costs. We have previously shown that HCV E2 glycoprotein is not highly immunogenic, and the modification of E2 reduced CD81 binding and displayed altered cytokine and protective immune responses

Indexed as

Hepatitis CViral Hepatitis VaccinesAnimalsHepacivirusHepatitis C AntibodiesHepatitis C AntigensHumansLeukocytes, MononuclearMiceRNA, MessengerViral Envelope ProteinsViral VaccinesHepatitis C AntibodiesHepatitis C AntigensRNA, MessengerViral Envelope ProteinsViral Hepatitis VaccinesViral VaccinesB cell responseCD4+T cellsDCsHCVmodified E2

Identifiers

PMID38084956
PMCPMC10805031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.